• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Transplantation . Lung Transplantation for COVID-19 Pulmonary Sequelae

tetano

Editor, Senior Moderator
Transplantation


. 2022 Nov 21.
doi: 10.1097/TP.0000000000004428. Online ahead of print.
Lung Transplantation for COVID-19 Pulmonary Sequelae


Hiromu Kehara[SUP] 1 [/SUP], Chirantan Mangukia[SUP] 1 [/SUP], Gengo Sunagawa[SUP] 1 [/SUP], Sebastian A Iturra[SUP] 1 [/SUP], Roh Yanagida[SUP] 1 [/SUP], Mohammed Kashem[SUP] 1 [/SUP], Yuri Persidsky[SUP] 2 [/SUP], Kartik Shenoy[SUP] 3 [/SUP], Albert J Mamary[SUP] 3 [/SUP], Nathaniel Marchetti[SUP] 3 [/SUP], Francis Cordova[SUP] 3 [/SUP], Gerard J Criner[SUP] 3 [/SUP], Yoshiya Toyoda[SUP] 1 [/SUP], Norihisa Shigemura[SUP] 1 3 [/SUP]



Affiliations

Abstract

Background: The role of lung transplantation for coronavirus disease 2019 (COVID-19)-related lung failure is evolving as the pandemic persists.
Methods: From January 2021 to April 2022, 20 patients (median age 62 y; range 31-77) underwent lung transplantation for COVID-related lung failure at our institution. We reviewed their clinical and intraoperative characteristics and early outcomes including postoperative complications.
Results: Eleven patients (55%) had chronic lung disease when they contracted COVID-19. All 20 patients required hospitalization for antivirus treatment. Median lung allocation score was 74.7 (33.1-94.0). Thirteen patients (65%) underwent single-lung transplants, and 7 patients (35%) underwent double-lung transplants. Concomitant coronary artery bypass graft surgery was performed in 2 (10%) patients because of severe coronary artery disease. Postoperatively, venovenous extracorporeal membrane oxygenation was needed in 3 patients (15%) because of severe primary graft dysfunction; all were eventually weaned. Ten patients (50%) experienced deep venous thrombosis, and 1 eventually developed a major pulmonary embolus. The median intensive care unit stay and hospital stays were 6.5 d (3-44) and 18 d (7-77), respectively. During a median follow-up of 201 d (47-418), we experienced 1 late mortality due to COVID-19-related myocarditis. Among the 13 patients with single-lung transplant, 5 demonstrated improvement in their native lungs.
Conclusions: Lung transplantation yielded favorable early outcomes in a heterogeneous patient cohort that included older patients, obese patients, and patients with coronary artery disease or preexisting chronic lung disease. Our data also shed light on the transforming role of lung transplantation for the pulmonary sequelae of a complex multisystem COVID-19 disorder.
 
Back
Top Bottom